Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Requirement On Site-specific Production Of Basic Drugs Removed in China’s Medical Reforms

This article was originally published in PharmAsia News

Executive Summary

The drafting of a basic drug system is an integral part of medical system reforms. After numerous reviews, a controversial article on "site-specific production and unified distribution of basic drugs" will be removed from the draft. Without this requirement, generic drug companies will have a more competitive edge. The pricing of basic drugs is another highlight of the draft. The government will set the retail price index for basic drugs. In addition, the compilation of a 2009 basic drug catalogue is continuing. The number of selected basic drugs has been cut to about 400 medicines from an original 756. (Click here for more



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts